1. Home
  2. MESO vs NBHC Comparison

MESO vs NBHC Comparison

Compare MESO & NBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • NBHC
  • Stock Information
  • Founded
  • MESO 2004
  • NBHC 2009
  • Country
  • MESO Australia
  • NBHC United States
  • Employees
  • MESO N/A
  • NBHC N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • NBHC Major Banks
  • Sector
  • MESO Health Care
  • NBHC Finance
  • Exchange
  • MESO Nasdaq
  • NBHC Nasdaq
  • Market Cap
  • MESO 1.4B
  • NBHC 1.4B
  • IPO Year
  • MESO N/A
  • NBHC 2012
  • Fundamental
  • Price
  • MESO $10.97
  • NBHC $36.97
  • Analyst Decision
  • MESO Buy
  • NBHC Hold
  • Analyst Count
  • MESO 4
  • NBHC 5
  • Target Price
  • MESO $18.00
  • NBHC $46.80
  • AVG Volume (30 Days)
  • MESO 156.4K
  • NBHC 296.1K
  • Earning Date
  • MESO 02-26-2025
  • NBHC 04-22-2025
  • Dividend Yield
  • MESO N/A
  • NBHC 3.13%
  • EPS Growth
  • MESO N/A
  • NBHC N/A
  • EPS
  • MESO N/A
  • NBHC 2.89
  • Revenue
  • MESO $5,670,000.00
  • NBHC $389,883,000.00
  • Revenue This Year
  • MESO $152.37
  • NBHC $13.64
  • Revenue Next Year
  • MESO $336.12
  • NBHC $6.70
  • P/E Ratio
  • MESO N/A
  • NBHC $12.84
  • Revenue Growth
  • MESO N/A
  • NBHC N/A
  • 52 Week Low
  • MESO $5.78
  • NBHC $32.83
  • 52 Week High
  • MESO $22.00
  • NBHC $51.76
  • Technical
  • Relative Strength Index (RSI)
  • MESO 44.34
  • NBHC 53.69
  • Support Level
  • MESO $10.77
  • NBHC $35.86
  • Resistance Level
  • MESO $11.61
  • NBHC $37.42
  • Average True Range (ATR)
  • MESO 0.47
  • NBHC 0.92
  • MACD
  • MESO 0.09
  • NBHC 0.30
  • Stochastic Oscillator
  • MESO 27.68
  • NBHC 87.74

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About NBHC National Bank Holdings Corporation

National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit card, wire transfer, automated clearing house, and electronic bill payments.

Share on Social Networks: